MYC and breast cancer: In the context of our findings, it is interesting to note that studies in mouse models of metastatic breast cancer has demonstrated the potential utility of combining PI3K and BET inhibitors to overcome a MYC-dependent feedback mechanism that limits the benefit of single-agent PI3K pathway inhibition in this context [54].